Tailored DNA Vaccine Extends Survival in Aggressive Glioblastoma
A phase 1 trial of GNOS-PV01, a personalized DNA vaccine for unmethylated MGMT glioblastoma, is safe and elicits broad immune responses by targeting up to 40 patient-specific neoantigens, transforming the tumor microenvironment from cold to hot and reducing the likelihood of tumor escape; results show two-thirds progression-free at six months and two-thirds overall survival at one year, with one patient recurrence-free nearly five years post-diagnosis, supporting larger trials and expansion to all GBM types.
